rs2291725 — GIP Ser103Gly

Missense variant in the GIP incretin hormone that changes its bioactivity and serum stability, with the derived Gly allele showing higher receptor activation and positive selection in Eurasian populations

See your personal result for GIP

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

GIP Ser103Gly — When Your Gut Hormone Fires at Full Strength

Every time you eat, your small intestine releases a hormone called GIP (glucose-dependent insulinotropic polypeptide)11 GIP (glucose-dependent insulinotropic polypeptide)
Also called gastric inhibitory polypeptide. One of two major incretin hormones that amplify insulin release after a meal and suppress appetite via the gut-brain axis. GIP works alongside GLP-1 to drive up to 70% of the insulin your pancreas secretes after eating — a system called the incretin effect. The rs2291725 variant in the GIP gene changes a single amino acid at position 103 of the precursor protein (Serine → Glycine), altering the bioactivity of the mature hormone.

This variant is unusual in human genetics: the Glycine form (C allele on the plus strand) appears to have undergone positive selection22 positive selection
Evolutionary selection where a beneficial variant spreads faster through a population than neutral drift would explain in Eurasian populations roughly 8,100 years ago — approximately when agriculture was expanding across Eurasia. The derived allele now reaches 71.8% in East Asian populations and 52.7% in Europeans, while remaining rare in African populations (11.6%), where the ancestral Serine form predominates at 88.4%.

The Mechanism

The Ser→Gly substitution at GIP amino acid 55 (position 103 in the prepropeptide) alters the biochemical behavior of the mature hormone in two ways, as shown by Chang et al. 201133 Chang et al. 2011
Chang CL et al. Adaptive selection of an incretin gene in Eurasian populations. Genome Research, 2011:

First, the Gly variant (C allele, GIP55G) generates significantly higher cAMP44 cAMP
Cyclic AMP — the intracellular second messenger that GIP triggers in pancreatic beta cells and adipocytes to drive insulin secretion production in GIPR-expressing cells compared to the ancestral Ser form (GIP55S), with a statistically significant difference (p < 0.01). This means stronger receptor activation per molecule of hormone released.

Second, the Gly variant is more resistant to serum degradation, giving the hormone a longer effective half-life in circulation. The ancestral Ser form is cleaved more readily by dipeptidyl peptidase-4 (DPP-4)55 dipeptidyl peptidase-4 (DPP-4)
The enzyme that rapidly inactivates both GIP and GLP-1 by removing their first two amino acids; DPP-4 inhibitors (gliptins) work by blocking this degradation, shortening its active window. Together, higher intrinsic potency and greater stability mean carriers of the Gly allele experience more powerful postprandial incretin signaling per meal.

GIP receptors are expressed not only in the pancreas and adipose tissue but also in the hypothalamus, hippocampus, and brainstem — areas that regulate appetite, reward, and the sleep-wake interface. This gut-brain axis expression explains why GIP variation appears in large-scale GWAS of sleep phenotypes alongside its better-characterized metabolic roles.

Importantly, GIP is one of two targets of tirzepatide (Mounjaro / Zepbound), the dual GIP/GLP-1 receptor agonist. Genetic variation in GIP and GIPR (the receptor gene) is increasingly recognized as relevant to treatment response prediction for this drug class.

The Evidence

Chang et al. (2011)66 Chang et al. (2011)
Chang CL et al. Adaptive selection of an incretin gene in Eurasian populations. Genome Research, 2011 analyzed 944 individuals across global populations from the HGDP-CEPH cohort and identified clear signatures of positive selection for the derived C allele in Eurasian — particularly East Asian — populations. The empirical selection p-values ranged from 0.004 to 0.058 across population comparisons. In functional assays, GIP55G showed higher cAMP production (p < 0.01) and greater serum stability (p = 0.002) than GIP55S, suggesting that enhanced incretin response to dietary carbohydrate may have conferred survival advantage in agricultural societies.

A cardiovascular risk study in 666 Chinese type 2 diabetic patients by Ma et al. (2018)77 Ma et al. (2018)
Ma X et al. Genetic variability of the GIP gene is involved in premature coronary artery disease in Chinese patients with T2D. J Diabetes Res, 2018 found that, in individuals with premature CAD (men <55, women <65), carriers of the C allele had higher CAD risk than non-carriers (OR 1.627, p = 0.015), while T/T or T/C genotypes (with at least one ancestral T allele) were associated with lower CAD risk (adjusted OR 0.769, p = 0.013). This paradoxical finding — the higher-bioactivity allele conferring CAD risk in the context of established diabetes — suggests the relationship between GIP activity and cardiovascular outcomes is mediated by metabolic context rather than being a simple dose-response.

The Lane et al. (2019) insomnia GWAS88 Lane et al. (2019) insomnia GWAS
Lane JM et al. Biological and clinical insights from genetics of insomnia symptoms. Nature Genetics, 2019 conducted in 453,379 UK Biobank participants identified 57 genome-wide significant loci for insomnia symptoms, with mapped biological pathways enriched for gut-brain signaling and metabolic hormone networks. The GIP locus on chromosome 17q21 sits within a region showing pleiotropic associations across metabolic, sleep, and cardiovascular traits.

A large coronary artery disease GWAS by the CARDIoGRAMplusC4D Consortium (2011)99 by the CARDIoGRAMplusC4D Consortium (2011)
Schunkert H et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nature Genetics, 2011 confirmed the 17q21 locus — which encompasses GIP — as genome-wide significant for CAD (n > 22,000 cases).

Practical Actions

The key modifiable variable in GIP biology is meal timing and composition. GIP is secreted within minutes of eating fat and carbohydrate — its release is driven by nutrient contact with K-cells in the proximal small intestine. For carriers of the lower-bioactivity Ser allele (T/T), optimizing meal timing relative to sleep may help compensate for the weaker postprandial incretin signal. Finishing eating at least 3–4 hours before bed reduces the nocturnal GIP stimulation that can fragment sleep architecture in individuals with altered gut-brain hormonal signaling.

GIP also directly promotes fat storage in adipocytes (it upregulates LPL activity and promotes triglyceride uptake), so carriers of two copies of the T allele — with lower GIP bioactivity — may have different fat partitioning responses to high-fat vs high-carbohydrate diets than Gly/Gly carriers.

For users taking or considering tirzepatide (which agonizes both the GIP and GLP-1 receptors), variants in the GIP gene pathway are increasingly being studied as potential response modifiers. The ancestral Ser form (T allele) may be associated with lower endogenous GIPR activation, potentially altering the pharmacological response landscape.

Interactions

GIP works in concert with GLP-1 (encoded by GCG on chromosome 2) and the GIP receptor (GIPR, chromosome 19). GIPR variants — particularly rs1800437 (E354Q) — modify receptor sensitivity and are separately catalogued. The combined effect of GIP Ser103Gly (rs2291725) and GIPR variants on incretin potency and sleep quality is a plausible compound interaction: individuals with both a lower-bioactivity GIP ligand (T/T) and a reduced-sensitivity GIP receptor may have the most attenuated gut-brain incretin signaling.

The GIP locus at 17q21 lies near genes involved in coronary artery disease (UBE2Z, ATP5G1, SNF8). Functional interaction with rs46522 (UBE2Z-GIP locus) in the context of T2D risk has been reported, though this reflects LD structure rather than direct gene-gene interaction.

Drug Interactions

tirzepatide dose_adjustment literature
semaglutide dose_adjustment literature

Nutrient Interactions

dietary fat altered_metabolism
dietary carbohydrate altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

CC Enhanced Incretin Beneficial

Two copies of the derived Gly allele — highest GIP bioactivity

Both copies of your GIP gene encode the Gly55 form (GIP55G in the processed mature hormone). Functional assays show that this variant generates significantly higher cAMP in GIPR-expressing cells and is more resistant to DPP-4–mediated degradation than the ancestral Ser form. The practical consequence is a stronger and longer-lasting postprandial incretin signal per meal.

This genotype represents the dominant form in East Asian populations and is consistent with a selective advantage in populations that shifted to agricultural diets high in starch and fat. The evolutionary argument is that more efficient insulin secretion in response to carbohydrate improved metabolic fitness during the agricultural transition.

One caveat: in the context of type 2 diabetes plus early-onset CAD, Ma et al. 2018 found the C allele associated with higher CAD risk (OR ~1.6), suggesting that higher GIP activity in a metabolically stressed background can have adverse cardiovascular consequences. This is likely mediated by GIP's adipogenic effects (promoting fat storage via LPL) rather than its incretin effects per se.

CT Intermediate Incretin Intermediate

One copy each of the derived and ancestral allele — intermediate GIP bioactivity

With one copy each, you produce a mixture of the higher-bioactivity GIP55G and the lower-bioactivity, DPP-4-sensitive GIP55S peptide. The net incretin effect lies between the CC and TT extremes.

The evolutionary and metabolic implications are intermediate. The positive selection signal for the C allele suggests heterozygotes had a selective advantage over Ser homozygotes, but a smaller advantage than Gly homozygotes — consistent with a codominant model with partial penetrance.

For sleep-related phenotypes, the intermediate GIP bioactivity means your gut-brain incretin signaling is neither maximally efficient nor substantially impaired at this locus. Meal timing relative to bedtime is still a relevant modifiable factor, though the effect is smaller than in TT homozygotes.

TT Ancestral Incretin Decreased

Two copies of the ancestral Ser allele — lower GIP bioactivity

Both copies of your GIP gene encode the GIP55S (Ser) form, the peptide that was the original state before the Gly variant spread through Eurasian agricultural populations. The Ser form shows lower cAMP stimulation at the GIPR and is degraded faster by DPP-4, shortening the effective half-life of each secreted pulse.

The incretin consequence is a weaker per-molecule GIP signal following meals, though total GIP secretion (the amount of hormone released by K-cells) is not necessarily reduced — the deficit is in the downstream receptor activation efficiency and signal duration. This distinction matters: your GIP secretion is driven by the same fat- and carbohydrate-sensing mechanisms as everyone else; it is the effectiveness of each molecule that differs.

From a sleep perspective, lower GIP bioactivity means weaker postprandial gut-brain satiety signaling. GIP receptors in the hypothalamus and limbic regions contribute to the hormonal "fed state" signal that coordinates the post-meal rest phase. Attenuated GIP signaling from this variant may contribute to delayed sleep onset or lighter post-meal rest, though this mechanism is still being investigated.

The cardioprotective pattern seen in the Ma et al. 2018 data — where T allele carriers (Ser/Ser or Ser/Gly) had lower premature CAD risk in the context of type 2 diabetes — suggests the lower GIP adipogenic drive of the Ser form may be advantageous when metabolic disease is already established.